TO THE EDITOR: Some of the findings reported recently by Etchebehere et al. on the use of
223Ra in patients with metastatic castrate-resistant prostate cancer and the utility of baseline …

The purpose of this study was to evaluate outcome after 223Ra dichloride therapy (223Ra)
and to determine whether skeletal tumor burden on whole-body 18F-fluoride PET/CT can be …

Purpose Determine if skeletal tumor burden on 18 F-fluoride PET/CT (fluoride PET/CT)
predicts the risk of bone marrow failure (BMF) after 223 Ra dichloride therapy (223 Ra) …

TO THE EDITOR: We read with interest the article by Bucknor et al. titled,“Disparities in PET
Imaging for Prostate Cancer at a Tertiary Academic Medical Center”(1). The authors …

TO THE EDITOR: We read with great interest the article by Ron Epelbaum et al.(1) on the
use of dynamic 18F-FDG PET/CT to assess tumor aggressiveness and overall outcome in …

TO THE EDITOR: In prostate-cancer patients investigated with 18F-DCFPyL, a second-
generation 18F-labeled prostate-specific membrane antigen ligand, Jansen et al. have …

In July 2013 The New England Journal of Medicine published a randomised controlled
study demonstrating a survival benefit for castration-resistant prostate cancer (CRPC) …

TO THE EDITOR: An excellent recent review by Sgouros et al. on the multifaceted
complexities of tumor dose-response was highly informative (1). However, it did not address …

Aim To establish the utility of baseline 18 F-Fluorocholine (FCH) PET/CT and bone
scintigraphy (BS) in the outcome prediction of patients with castration-resistant prostate …

TO THE EDITOR: The study by Martin et al.(1) comparing PET/MRI and PET/CT suffers from
several methodologic concerns. Most importantly, all patients underwent PET/CT first and …